pgv001
Vaccineexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT01008527)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pgv001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05010200 | Phase 1 | Sep 30, 2021 | Icahn School of Medicine at Mount Sinai |
| NCT03359239 | Phase 1 | Sep 30, 2018 | Genentech, Icahn School of Medicine at Mount Sinai |
| NCT02721043 | Phase 1 | Apr 1, 2016 | Icahn School of Medicine at Mount Sinai |
| NCT01970358 | Phase 1 | Jan 1, 2014 | Harvard University |
| NCT01008527 | Phase 1 | Oct 1, 2009 | National Cancer Institute (NCI), Oncovir, Inc., Pfizer, University of South Florida |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 3 | 3 | 1 | 2016 |
| Genentech | For profit | 1 | 0 | 1 | 2018 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2009 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2009 |
| Pfizer | For profit | 1 | 0 | 1 | 2009 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2009 |
7 organizations
Page 1 / 1